GlassScriptPhysician profile
Elizabeth M Brown
NPI 1831604917
$4,767.14
in general payments reported to CMS, 2019-2025
26 companies · $1,293 in 2025
The $1,293 reported for 2025 was more than what 90% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $917 · 2022: $564 · 2023: $1,028 · 2024: $965 · 2025: $1,293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,286.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,241.62 | 2021-2025 | |
| Abbott Laboratories | $960.54 | 2021-2024 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit |
| Cvrx, INC. | $371.65 | 2023-2025 | Barostim Neo System |
| Lexicon Pharmaceuticals, INC. | $240.64 | 2023-2025 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $211.37 | 2023-2025 | Wainua, Fasenra, Farxiga |
| Abiomed | $199.11 | 2024-2025 | Impella |
| Itamar Medical INC | $194.73 | 2022-2025 | Watchpatone |
| Ancora Heart, INC. | $158.11 | 2025 | Accucinch |
| Zoll Respicardia, INC. | $156.34 | 2021 | |
| Inspire Medical Systems, INC. | $153.85 | 2025 | Inspire |
| Bridgebio Pharma, INC. | $147.27 | 2025 | Attruby |
| E.R. Squibb & Sons, L.L.C. | $125.60 | 2024-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $115.58 | 2023-2025 | Verquvo, Zerbaxa, Recarbrio |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $91.39 | 2023 | Lifevest |
| Novo Nordisk INC | $77.33 | 2021-2023 | Wegovy, Saxenda |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.31 | 2021-2024 | Ofev, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $49.37 | 2022 | |
| Daiichi Sankyo INC. | $28.39 | 2023 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $26.47 | 2024 | Dupixent |
| Medtronic, INC. | $26.38 | 2021 | |
| Genzyme Corporation | $25.87 | 2024 | |
| Philips North America LLC | $22.46 | 2025 | Vest Therapy Und |
| Dexcom, INC. | $22.14 | 2025 | Dexcom G6 Transmitter |
| Vifor Pharma, INC. | $21.88 | 2024 | Zemaira |
| Ani Pharmaceuticals, INC. | $20.47 | 2024 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $16.27 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.